MLYS — Mineralys Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1933414 ·
Last close
$25.27
Market Cap
$2.23B
52W High
$32.14
52W Low
$22.30
ADV30
709,866
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -45,340,000 | -39,339,000 | 652,862,000 | 112,779,000 | 14,718,000 |
| Dec 2025 | 0 | — | -38,280,000 | -32,234,000 | 661,806,000 | 172,921,000 | 15,113,000 |
| Sep 2025 | 0 | — | -41,131,000 | -36,932,000 | 599,947,000 | 217,597,000 | 23,520,000 |
| Jun 2025 | 0 | — | -46,746,000 | -43,274,000 | 335,724,000 | 101,788,000 | 22,173,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-136,400,000
Investing CF
$-341,820,000
Financing CF
$425,992,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.05
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-496,508,000
Inventory
—
Receivables
—
ST Investments
$533,281,000
EBIT TTM
$-171,497,000
Pretax Income TTM
$-151,779,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -170,604,000 | -154,651,000 | 661,806,000 | 15,113,000 | — | -142,416,000 |
| Dec 2024 | 0 | -192,403,000 | -177,810,000 | 205,903,000 | 14,646,000 | — | -166,314,000 |
| Dec 2023 | 0 | -84,657,000 | -71,898,000 | 251,636,000 | 10,482,000 | — | -81,173,000 |
| Dec 2022 | 0 | -31,479,000 | -29,799,000 | 114,442,000 | 166,711,000 | — | -29,221,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-85,780,000
OpCashFlow TTM
$0
Assets (Latest)
$205,903,000
Forward EPS
$-2.50
Max Pain — expiry 2028-01-21
max pain strike: $30.00 · spot: $25.27 · call oi: 198 · put oi: 1,667
Expected Move to 2028-01-21:
±$19.50
(77.17%) —
implied range
$5.77 –
$44.77
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| HRMY | Harmony Biosciences Holdings, Inc. | $2.24B | $38.50 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.20B | $16.57 | — |
| URGN | UroGen Pharma Ltd. | $2.26B | $46.16 | — |
| GENB | Generate Biomedicines, Inc. | $2.27B | $17.72 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
News headlines (Yahoo Finance, 1h cache)
Mineralys (MLYS) Q2 2026 Earnings Call Transcript
2026-08-18 23:13 · Yahoo
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13 20:05 · Yahoo
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
2026-08-12 05:01 · Yahoo
Mineralys Therapeutics Q2 Earnings Call Highlights
2026-08-11 23:04 · Yahoo
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 20:05 · Yahoo
Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View
2026-08-05 11:10 · Yahoo
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-07-27 20:01 · Yahoo
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date
2026-07-16 21:05 · Yahoo
What to Know About This Mineralys Insider Sale Before a December FDA Date
2026-07-16 20:57 · Yahoo
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger
2026-07-03 13:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.